Takeda Biopharmaceuticals India Private Limited (formerly Baxalta Bioscience India Pvt Ltd) – a global values-based, R&D-driven biopharmaceutical leader in innovative healthcare solutions presented an industry perspective on equitable access to healthcare during the 5th edition of the Confederation of Indian Industry (CII) UP Health Summit “Empowering Wellness: Transforming Lives for a Healthy Future”.The summit serves as a crucial platform for bringing together policymakers, industry leaders and experts to deliberate on pressing healthcare challenges and opportunities.
Michelle Erwee, Global Head of Access to Medicines, Takeda delivering keynote address at the inaugural session of the 5th edition of CII UP Health Summit
In her keynote address, Michelle Erwee, Global Head of Access to Medicines, Takeda said, “At Takeda, we are committed to accelerating global, equitable access to our medicines and vaccines. Whilst we know every individual, country and community often face their own unique barriers to access, availability of medicines, capacity within local healthcare systems, and affordability are common challenges that require a collaborative and innovative approach. We acknowledge that the Government of India continues to prioritise initiatives aimed at enhancing the accessibility and equity of health services, and we remain open to collaboration in order to advance access to medicines for patients in need.”
Ruchi Sogarwal, Head of Corporate Affairs, Takeda India added, “The Government of India has implemented value-based healthcare measures through large-scale initiatives such as Pradhan Mantri Jan Aarogya Yojana and Ayushman Bharat Digital Mission to improve and scale the delivery of healthcare services to all. Specifically in Uttar Pradesh – the most populus state of the country – the government is taking transformative measures to advance healthcare infrastructure and eliminating barriers to care across patient pathways. We believe India’s G20 Presidency will give a fillip to its initiatives to boost healthcare access while the success of our government schemes could inspire other nations across the globe to emulate this model.”
Takedas representation at the CII UP Health Summit resonates with its commitment to catalyzing positive change in the healthcare landscape. Through collaborative efforts and innovative solutions, Takeda India aims to continue driving progress and access to quality healthcare, in line with its purpose of Better Health and a Brighter Future for people around the world.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
For more information, visit www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: www.takeda.com/investors/sec-filings or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.